Baidu
map
TECHNOL CANCER RES T 润色咨询

TECHNOLOGY IN CANCER RESEARCH & TREATMENT

出版年份:2002 年文章数:1646 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:6.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2022-07-07 123b4903m95暂无昵称

    proof到online要多久,有没有大神回答一下?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-03-10 997xiu 来自上海

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……
    20230306 submitted
    0308 Administrative checks complete……

    11

    展开11条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2024-03-27 芊芊010101 来自上海

    审稿速度:1.0
    偏重的研究方向:肿瘤;长链非编码RNA
    经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2022-12-22 不懂科研的科研狗子 来自北京

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:消化道肿瘤;水凝胶
    经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:
    2022-6-21号投稿 Initial Checks,
    6-23号更新投稿 Initial Checks,
    6-24号Initial checks have been completed and Editor assignment is being determined,
    6-27号Editor assessment The Editor is assessing your submission for peer review,
    6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,
    7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,
    8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,
    8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,
    8-19号通知大修,
    9-11号R1修回,
    10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,
    11-06号催稿信,
    12-01号通知二次返修,
    12-13号R2修回,
    12-22号Accept Admin completing pre-production checks.

    5

    展开5条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-12-02 ms6000001587552606 来自江苏省

    请问这个期刊是必须交版面费吗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-03-15 旧喜 来自江苏省

    投稿命中率:75.0
    偏重的研究方向:肿瘤;长链非编码RNA
    经验分享:Received: December 30, 2021;
    Revised: June 5, 2022;
    Accepted: July 4, 2022
    两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。
    没有太多的波折

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-02-15 纯绿色无污染 来自甘肃省

    Wos到现在去年的没有收录,怎么回事?

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2022-11-24 1801f0d947m 来自江西省

    6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-01-31 ms6000001015003171 来自上海

    偏重的研究方向:肿瘤
    经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1231140, encodeId=a6b612311402e, content=proof到online要多久,有没有大神回答一下?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76042430158, createdName=123b4903m95暂无昵称, createdTime=Thu Jul 07 14:11:53 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118737, encodeId=50ff2118e377e, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:做个记录,一篇关于罕见转移的临床回顾性研究……<br>20230306 submitted<br>0308 Administrative checks complete……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=997xiu, createdTime=Fri Mar 10 23:08:33 CST 2023, time=2023-03-10, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195607, encodeId=7753219560ea3, content=审稿速度:1.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:3/22投稿状态是initial checks; 3/27看状态又变回submitted,这是被拒了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75915442878, createdName=芊芊010101, createdTime=Wed Mar 27 09:11:57 CST 2024, time=2024-03-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2107072, encodeId=9185210e072ab, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:消化道肿瘤;水凝胶<br>经验分享:我会经常在梅斯上看大家的经验,想着我要是有经验了也来给大家反馈一下,互相帮助共渡毕业大关:<br>2022-6-21号投稿 Initial Checks,<br>6-23号更新投稿 Initial Checks,<br>6-24号Initial checks have been completed and Editor assignment is being determined,<br>6-27号Editor assessment The Editor is assessing your submission for peer review,<br>6-30号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>7-4号邮件告知UnderReview,Reviewers assigned and awaiting reviewer scores Reviewers have been assigned and are completing reviews,<br>8-1号Reviewer invitation and assignment in process Reviewers are being invited and responses are being received,<br>8-15号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>8-19号通知大修,<br>9-11号R1修回,<br>10-24号Reviews returned - awaiting Editor assessment The Editor is considering the reviews and recommendations in order to make decision on your submission,<br>11-06号催稿信,<br>12-01号通知二次返修,<br>12-13号R2修回,<br>12-22号Accept Admin completing pre-production checks., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211124/1e5cd5d4efd7465caf5bd5b725ef80a1/3ece342b14e94d08bab19d7ff6d8dadd.jpg, createdBy=a3015646862, createdName=不懂科研的科研狗子, createdTime=Thu Dec 22 16:38:20 CST 2022, time=2022-12-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172513, encodeId=eb0421e251330, content=请问这个期刊是必须交版面费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7108512699, createdName=ms6000001587552606, createdTime=Sat Dec 02 15:37:22 CST 2023, time=2023-12-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119636, encodeId=13dc211963653, content=投稿命中率:75.0<br>偏重的研究方向:肿瘤;长链非编码RNA<br>经验分享:Received: December 30, 2021; <br>Revised: June 5, 2022; <br>Accepted: July 4, 2022<br>两个审稿人,第一个补了点实验,第二个拒稿。补充实验后再投,没多久就接受了。<br>没有太多的波折, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/7184D5A73183D553B3C5EF64FAA03D5F/100, createdBy=8f3c2428741, createdName=旧喜, createdTime=Wed Mar 15 20:19:52 CST 2023, time=2023-03-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2114813, encodeId=98e3211481342, content=Wos到现在去年的没有收录,怎么回事?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bd72337833, createdName=纯绿色无污染, createdTime=Wed Feb 15 21:59:36 CST 2023, time=2023-02-15, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2102410, encodeId=1d99210241079, content=6月初投稿,9月外审,两次大修及润色,这周接受,还没收到invoice,不知道多少钱 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQD7lFVWLp95HhETAbICUnK8Lfwclhic48NYfWpzve4icQhTReAPbm7RCjXaFMHibgvNNkpwXd9aGHg/132, createdBy=b5212074587, createdName=1801f0d947m, createdTime=Thu Nov 24 14:40:00 CST 2022, time=2022-11-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2112406, encodeId=7e712112406d0, content=偏重的研究方向:肿瘤<br>经验分享:三个月了还在邀请审稿人。。纠结要不要撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11248355803, createdName=ms6000001015003171, createdTime=Tue Jan 31 16:36:12 CST 2023, time=2023-01-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2112898, encodeId=a3b32112898a3, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肺癌<br>经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a4d5395766, createdName=ms5000000653748257, createdTime=Fri Feb 03 16:30:49 CST 2023, time=2023-02-03, status=1, ipAttribution=北京)]
    2023-02-03 ms5000000653748257 来自北京

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:肺癌
    经验分享:一篇综述6月投的,11月返回,2个小修一个拒稿,一周修回,12月见刊

    0

共275条页码: 1/28页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map